Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Rigosertib in Transfusion-dependent MDS
NCT01584531Phase 2Completed
- Sponsor
- Traws Pharma, Inc.
- Start
- May 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rigosertib in myelodysplastic syndrome (MDS), sponsored by Traws Pharma, Inc.. Started May 2012; status: completed.
02
Drugs
rigosertib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT01584531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01584531.